Stabilizing GPCR Mutants for Crystallization via Ligand Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
G protein-coupled receptors (GPCRs) are challenging to crystallize due to their instability in detergent solutions and existence in multiple conformations, which hinders structure determination and drug development efforts.
Innovation Solution
Mutant GPCRs with increased stability and conformational thermostability are selected through specific amino acid replacements and ligand binding, allowing for improved stability and locking in biologically relevant conformations, facilitating crystallization and drug discovery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If eukaryotic membrane proteins are expressed using standard techniques, then they can be produced for structural studies, but they exhibit poor stability in detergent solutions leading to denaturation or precipitation
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid substitutions at defined positions in the GPCR sequence. These mutations alter the protein's physical-chemical properties to enhance detergent stability while maintaining expression feasibility. The systematic modification of amino acid parameters at critical positions resolves the contradiction between stability and ease of manufacture.
Solution Approach 2:
The patent creates simplified copies or variants of the native GPCR by introducing stabilizing mutations. These mutant versions replicate the essential functional properties of the original protein while possessing improved stability characteristics, allowing them to serve as effective substitutes for structural studies without requiring complex expression protocols.
2Ease of manufacture
If detergents with short aliphatic chains and small or charged head groups are used for crystallisation, then crystal growth is facilitated, but the membrane proteins become destabilised and denature
Solution Approach 1:
The patent applies preliminary action by pre-stabilizing the GPCR through specific amino acid mutations before the crystallisation process. This preliminary stabilization ensures that the protein can withstand the destabilizing effects of harsh detergents during subsequent crystallisation steps, allowing crystal growth without denaturation.
Solution Approach 2:
The stabilizing mutations act as a protective cushion against the destabilizing effects of harsh detergents. By introducing these mutations beforehand, the protein gains inherent resistance to denaturation, cushioning it against the harsh conditions required for crystal growth with short-chain detergents.
3Reliability
If GPCRs are purified from natural sources, then they maintain stability in detergent solutions, but overexpression in eukaryotic systems becomes extremely difficult
Solution Approach 1:
The patent modifies the GPCR's amino acid parameters to enhance its intrinsic stability, allowing it to be overexpressed in eukaryotic systems with improved productivity. The specific mutations change the protein's physical properties to match the stability characteristics of naturally sourced proteins, enabling both high expression levels and detergent stability.
4Adaptability or versatility
If GPCRs exist in multiple conformations, then they reflect their functional dynamics, but this conformational heterogeneity hinders crystallisation and structure determination
Solution Approach 1:
The patent extracts or selects specific stabilizing mutations from the vast sequence space and applies them to the GPCR. These selected mutations preferentially stabilize one conformation over others, effectively extracting the desired conformational state from the ensemble of functional conformations, thereby enabling crystallisation while preserving essential functional characteristics.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method for selecting a G-protein coupled receptor (GPCR) with increased stability, the method comprising (a) providing one or more mutants of a parent GPCR, (b) selecting a ligand, the ligand being one which binds to the parent GPCR when the GPCR is residing in a particular conformation, (c) determining whether the or each mutant GPCR has increased stability with respect to binding the selected ligand compared to the stability of the parent GPCR with respect to binding that ligand, and (d) selecting those mutants that have an increased stability compared to the parent GPCR with respect to binding the selected ligand. Mutants of β-adrenergic receptor, adenosine receptor and neurotensin receptor are also disclosed.